Join us for an unmissable evening on the future of CGT manufacturing! Matthew Hewitt, VP CTO Manufacturing Charles River Labs & Jason C. Foster will present new insights & demos of the IRO platform. 🕠9/17 17:00 🏨Four Seasons Hotel Dalton, Boston Don’t miss out➡️oribiotech.com/news/experienc…

🧬 Why should life-saving therapies only target high-population diseases? Anshul Mangal, Project Farma, joined Jason C. Foster on the Ori Spotlight Podcast to discuss the importance of scalable manufacturing platforms in treating the rarest diseases. 🎧:open.spotify.com/episode/7ooaaC…

🔬Recent studies show racial & socioeconomic disparities in CAR-T therapy access for lymphoma, leading to underrepresentation & poorer outcomes. With IRO® we empower scientists to Automate Better Biology™ & help life-saving therapies reach more patients➡️healthtree.org/dlbcl/communit…

🦾 With IRO® we’re setting a new standard for cell therapy manufacturing. With data from 650+ runs, multiple donors & cell types, we offer flexibility & scalability to tackle CGT manufacturing challenges. Want to see what RO can do for you? Book a demo➡️ oribiotech.com/iro#schedule-a…

Alla's melanoma continued to spread despite surgery, chemo and radiotherapy. That was until early 2024, when Alla received TIL therapy at UChicago Medicine. Increasing #PatientAccess to advanced therapies will help others like Alla to reclaim their lives ⬇️ uchicagomedicine.org/forefront/canc…

👀 Are you curious to see how IRO® could work for you? 🕔09.17, 5pm ET 📍Four Seasons Hotel Dalton, Boston Join us for an evening of live in-person IRO demos and new real-world IRO data from Jason C. Foster and Matthew Hewitt, Charles River Labs. Register➡️oribiotech.com/news/experienc…

🧬Vered Caplan, CEO of Orgenesis, believes rethinking cell therapy #manufacturing is integral to making these life-changing therapies accessible. Listen to her full conversation with Jason C. Foster, on the #OriSpotlight podcast: open.spotify.com/episode/7lXpcp…

🔬 Could CAR-T be the key to treating disorders like multiple sclerosis and lupus? nature looks at some of the latest CAR-T developments for treating autoimmune disorders, including R&D activity by Kyverna Therapeutics and CRISPR Therapeutics. Read more ➡️nature.com/articles/s4158…

In a new interview with The Medicine Maker, Ori CEO, Jason C. Foster & Jason Bock, CTMC CEO & co-founder, discuss why scalable #CellTherapy #Manufacturing will help meet the rapidly growing demand for #CellTherapies. Read the full discussion: themedicinemaker.com/manufacture/ne…

🔬 Diagnosed with myeloma in 2007, Mindy faced a 16-year battle. In 2023, she chose CAR-T therapy for its "one-and-done" treatment. One year later, Mindy is in complete remission and enjoying life with her family. Thanks CURE Today for sharing ➡️curetoday.com/view/my-decisi…

For CGTs to be successful, joined-up solutions are required across the therapeutic journey Deloitte's Omkar Kawalekar believes the key lies in aligning every aspect of #manufacturing and treatment delivery, like a well-coordinated orchestra. 🎧Spotify: open.spotify.com/episode/6GMcWP…

⏰ The countdown has begun! Join us on September 17 to experience IRO in-person with live demos and new head-to-head d IRO data presentations. 🕔 5:00 PM ET 📍 Four Seasons Hotel Dalton Spaces are filling up fast, secure your spot ➡️ oribiotech.com/news/experienc…

The Alliance for Regenerative Medicine (ARM) has released its latest Sector Snapshot, shedding light on the CGT developments shaping 2024. So far: 🧬5 CGT therapies have been approved in the US and EU 🩺1,851 CGT clinical trials are ongoing Read the full report ➡️ alliancerm.org/wp-content/upl…

Automation is key to advancing the future of #CellTherapy... That's why we built IRO®. IRO delivers superior biological performance, alongside the benefits of automation, to maximize clinical and commercial impact. Schedule a demo today ➡️ oribiotech.com/iro#schedule-a…

🔬 According to CAR-T pioneer Dr. Carl June, 2024 is shaping up to be a breakthrough year for CAR-T cell therapy in the treatment of glioblastoma. Dr June shared his insights with Juergen Eckhardt at Forbes ⬇️ forbes.com/sites/juergene…

📅 Just 7 days until you can experience IRO® at our event in Boston! 📍 09/17, 5pm ET | Four Seasons Hotel Dalton Join Jason C. Foster & Matthew Hewitt from Charles River Labs for live IRO demos and new head-to-head data presentations. Secure your spot: oribiotech.com/news/experienc…

🔬A scalable, viable product is key to staying ahead in CGT Jason C. Foster and Carl Schoellhammer from DeciBio discuss how viability and automation, inside and outside the lab, are essential to successfully bring CGTs to market. 🎧 Spotify: open.spotify.com/episode/7ooaaC…

🔬#Manufacturing bottlenecks are driving a decline in investment in cell & gene therapy developers Addressing these bottlenecks is key to ensuring long-term viability of CGTs – ensuring these therapies are able to meet growing #PatientDemand Read more:biopharmadive.com/news/cell-gene…

With more CAR-T therapies approved each year, how many patients are being treated? Since 2022, we've analyzed external data to track the number of patients who have accessed commercially available CAR-T therapies. We've updated the latest Q2 figures➡️ oribiotech.com/news/patient-a…

🔬 Elizabeth was diagnosed with multiple myeloma in 2009. After years of treatments, she participated in a CAR-T clinical trial through Dana-Farber earlier this year. Within a week, she felt well enough to return to work. Thanks Dana-Farber for sharing: blog.dana-farber.org/insight/2024/0…